<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698173</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2022/53</org_study_id>
    <nct_id>NCT05698173</nct_id>
  </id_info>
  <brief_title>Systemic Lupus Erythematosus and Accelerated Aging</brief_title>
  <acronym>LUPAGE</acronym>
  <official_title>Systemic Lupus Erythematosus and Accelerated Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at evaluating the phenomena of immune system aging in patients with Systemic&#xD;
      lupus erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by&#xD;
      a breakdown of tolerance against nuclear antigens. Thanks to improvements during the last&#xD;
      decades in diagnosis, therapeutics and medical care, the lifespan of SLE patients has&#xD;
      remarkably increased. However, standardized mortality ratio are still high in this&#xD;
      population, with an increased mortality and morbidity associated with cardiovascular events&#xD;
      and infectious events. Interestingly, these conditions are more commonly found during old age&#xD;
      in the general population, raising the question of the presence of an acceleration of the&#xD;
      aging process in SLE patients.&#xD;
&#xD;
      It has been demonstrated that the aging of the immune system, i.e. immunosenescence, is a key&#xD;
      player in the development of many age-related diseases. The acceleration of immunosenescence,&#xD;
      as it is observed during chronic viral infections for example, could favor the premature&#xD;
      occurrence of clinical manifestations of accelerated aging. The exact contribution of such&#xD;
      phenomenon in the context of SLE has, so far, never been explored.&#xD;
&#xD;
      Here, the investigators propose to perform a comprehensive study of the phenomena of immune&#xD;
      system aging in patients with SLE in comparison to age-matched healthy controls.&#xD;
&#xD;
      The study will recruit 50 SLE patients followed in Bordeaux University Hospital. Among&#xD;
      classical disease activity information, blood samples will be collected at study visit to&#xD;
      extensively evaluate immune system aging. Fundamental research will be realized on patients'&#xD;
      samples. Patients will be included within their usual follow-up. No extra visit will be&#xD;
      needed, and blood samples will be drawn at the same time as those drawn for clinical&#xD;
      purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2023</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute numbers of naïve T lymphocytes</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute numbers of terminally differentiated T lymphocytes</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of terminally differentiated T lymphocytes among total lymphocytes</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of senescent lymphocytes among total lymphocytes</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telomere length in sorted CD4+ and CD8+ T lymphocytes subsets (naïve and memory)</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and phenotype of ELA-specific CD8+ T-cells after 10 days of in vitro priming</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of naïve T lymphocytes newly produced by thymus evaluated by T-cell receptor excision circles (TRECs) measurement</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of senescence-associated secretory phenotype (SASP) markers in patients sera</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of anti-type I interferons autoantibodies in patients sera</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of disease activity according to British Lupus Assessment Group Index 2004 (BILAG-2004)</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of organ damage according to SLICC/ACR Damage Index</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of anti-double stranded DNA in patients sera</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of complement components C3 and C4 in patients sera</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnosis of systemic lupus erythematosus according to American College of Rheumatology (ACR) or SLICC criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation</description>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood for Peripheral blood mononuclear cell (PBMC) and serum isolation</description>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female;&#xD;
&#xD;
          -  age between 18 and 60 years;&#xD;
&#xD;
          -  Lupus patient : diagnosis of systemic lupus erythematosus according to ACR or SLICC&#xD;
             criteria;&#xD;
&#xD;
          -  being affiliated to health insurance;&#xD;
&#xD;
          -  willing to participate and to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breastfeeding women;&#xD;
&#xD;
          -  persons deprived of their liberty by a judicial or administrative decision, minors,&#xD;
             persons of legal age who are the object of a legal protection measure or unable to&#xD;
             express their consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noemie GENSOUS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noemie GENSOUS, MD</last_name>
    <phone>(0)5 56 79 58 28</phone>
    <phone_ext>+33</phone_ext>
    <email>noemie.gensous@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux - Médecine Interne et Immunologie Clinique</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Noemie GENSOUS, MD</last_name>
      <phone>(0)5 56 79 58 28</phone>
      <phone_ext>+33</phone_ext>
      <email>noemie.gensous@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Noemie GENSOUS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe RICHEZ, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel COUZI, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estibaliz LAZARO, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>December 21, 2022</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>Aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

